Tradewinds Capital Management LLC Has $60,000 Holdings in Amgen Inc. (NASDAQ:AMGN)

Tradewinds Capital Management LLC boosted its position in Amgen Inc. (NASDAQ:AMGN) by 39.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 211 shares of the medical research company’s stock after buying an additional 60 shares during the quarter. Tradewinds Capital Management LLC’s holdings in Amgen were worth $60,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Diversified Trust Co boosted its holdings in Amgen by 76.8% in the 4th quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock valued at $10,857,000 after purchasing an additional 16,376 shares during the period. Provence Wealth Management Group boosted its holdings in Amgen by 11.9% in the 4th quarter. Provence Wealth Management Group now owns 1,445 shares of the medical research company’s stock valued at $416,000 after purchasing an additional 154 shares during the period. Kinsale Capital Group Inc. boosted its holdings in Amgen by 33.0% in the 4th quarter. Kinsale Capital Group Inc. now owns 11,348 shares of the medical research company’s stock valued at $3,269,000 after purchasing an additional 2,814 shares during the period. Global Wealth Management Investment Advisory Inc. boosted its holdings in Amgen by 2.4% in the 4th quarter. Global Wealth Management Investment Advisory Inc. now owns 4,733 shares of the medical research company’s stock valued at $1,363,000 after purchasing an additional 109 shares during the period. Finally, Traynor Capital Management Inc. boosted its holdings in Amgen by 9.5% in the 4th quarter. Traynor Capital Management Inc. now owns 18,941 shares of the medical research company’s stock valued at $5,455,000 after purchasing an additional 1,650 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Down 1.0 %

Shares of AMGN stock traded down $3.24 during trading on Wednesday, reaching $307.53. The company’s stock had a trading volume of 446,332 shares, compared to its average volume of 2,754,962. The business has a fifty day moving average price of $303.09 and a 200-day moving average price of $292.80. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96. The company has a market cap of $164.97 billion, a price-to-earnings ratio of 44.50, a price-to-earnings-growth ratio of 2.82 and a beta of 0.58. Amgen Inc. has a one year low of $218.44 and a one year high of $329.72.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20. The business had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The firm’s revenue for the quarter was up 22.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.98 earnings per share. Analysts anticipate that Amgen Inc. will post 19.47 earnings per share for the current year.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the company’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total value of $662,811.53. Following the transaction, the senior vice president now directly owns 9,883 shares in the company, valued at $3,094,268.47. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.69% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. BMO Capital Markets raised their price objective on shares of Amgen from $336.00 to $355.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Mizuho raised their price objective on shares of Amgen from $223.00 to $235.00 and gave the stock a “neutral” rating in a report on Thursday, May 9th. StockNews.com raised shares of Amgen from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Barclays raised shares of Amgen from an “underweight” rating to an “equal weight” rating and lifted their price target for the company from $230.00 to $300.00 in a report on Friday, May 3rd. Finally, Royal Bank of Canada lifted their price target on shares of Amgen from $328.00 to $332.00 and gave the company an “outperform” rating in a report on Friday, June 14th. Ten investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, Amgen currently has a consensus rating of “Moderate Buy” and an average price target of $307.35.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.